Abstract: The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.

Abstract: The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

Abstract: Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

Abstract: The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

Abstract: The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by magnetic resonance image-guided radiation therapy in a subject in need thereof, said method comprising the steps of: (i) administering an efficient amount of high-Z element containing nanoparticles having, contrast enhancement for magnetic resonance imaging and/or radiosensitizing properties for radiation therapy, in a subject in need thereof, and, (ii) exposing said subject to magnetic resonance image-guided radiation therapy by means of a Magnetic Resonance Imaging Guided Linear Accelerator (MR-Linac), wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40, preferably higher than 50, and said nanoparticles have a mean hydrodynamic diameter below 20 nm, for example between 1 and 10 nm, preferably between 2 and 8 nm.

Abstract: The invention relates to a statistical polysaccharide with a weight-average molecular weight of between 100 kDa and 1000 kDa of the following formula (I): in which: each Rc independently represents a group containing a chelating agent, each Z independently represents a binder which may be a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said chain able to be either linear or branched and being able to contain one or more unsaturations and being able to contain one or more heteroatoms, preferably chosen from nitrogen, oxygen, sulfur and atoms of the halogen family, x is between 0.005 and 0.7, preferably between 0.05 and 0.7, and preferentially between 0.2 and 0.6, y is between 0.01 and 0.7, preferably between 0.05 and 0.2, the ratio of y/x being greater than or equal to 0.05, preferably greater than or equal to 0.15, and the sum of x+y being greater than or equal to 0.30, preferably greater than or equal to 0.35.

Abstract: The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.

Abstract: The present invention relates to the field of medical devices, more particularly the field of devices for extracting circulating molecules from the blood of a mammal, and their therapeutic uses, in particular in treating sepsis, cytokine release syndrome and/or any other form of systemic inflammatory response or cytokine shock, caused by bacterial, parasitic, fungal or viral infections, in particular caused by a viral infection, for example coronaviruses with human respiratory tract tropism.

Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRD and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.

Abstract: Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: The invention relates to a method for synthesizing ultrasmall silica nanoparticles, useful in particular for diagnostics and/or therapy. More specifically, a method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: —the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0?A?6, —the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0?B?5, —the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0<C?8. The invention also relates to the obtained ultrasmall silica nanoparticles.

Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.

Abstract: The present disclosure relates to a method for treating tumours. In particular, the invention relates to a new therapeutic use of nanoparticles as a sensitiser agent to radiofrequency radiation. More particularly, the invention relates to the use of nanoparticles in combination with radiofrequency radiations for the treatment of tumours, the radiofrequencies inducing hyperthermia of said tumour comprising the nanoparticles in the patient.

Abstract: The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

Abstract: The invention concerns the field of medical devices, more particularly devices for joint extraction, within an organism, of at least one metal cation and at least one target molecule. In order to do this, the device comprises: a) at least one ligand exhibiting specific affinity for the target molecule; b) at least one means for extraction of the metal cation, said means being a perfusion fluid comprising at least one chelating agent, the perfusion fluid being contained in a dialysis or microdialysis system. The use of these devices makes it possible, for example, to prevent and/or treat pathologies linked to dysregulation of the homeostasis of metals and/or target molecules in the organism, for example neurological diseases and/or proteinopathies.

Abstract: The present invention relates to the field of medical devices, more particularly to devices for extracting metals from an organism. The use of these devices makes it possible, for example, to prevent and/or treat pathologies linked to dysregulation of metal homeostasis in the organism, for example neurological diseases.

Abstract: The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.

Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies. The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.

Abstract: The invention relates to a method for synthesizing ultrasmall silica nanoparticles, useful in particular for diagnostics and/or therapy. More specifically, a method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: —the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0?A?6, —the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0?B?5, —the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0<C?8. The invention also relates to the obtained ultrasmall silica nanoparticles.